Distribution of paclitaxel in plasma and cerebrospinal fluid

Hans Gelderblom, Sharyn D. Baker, Ming Zhao, Jaap Verweij, Alex Sparreboom

Research output: Contribution to journalArticle

Abstract

Our objective was to assess the distribution of paclitaxel in plasma and cerebrospinal fluid (CSF) in a cancer patient, and evaluate the role of the formulation vehicle Cremophor EL (CrEL) in drug distribution. Analysis of paclitaxel concentrations in CSF was performed using a triple-quadrupole mass spectrometric assay with electrospray ionization. Total and unbound paclitaxel levels in plasma were measured by liquid chromatography and equilibrium dialysis, respectively, and CrEL concentrations were determined by a colorimetric dye-binding microassay. Clinical samples were obtained from a 54-year-old female with breast cancer receiving a weekly regimen of paclitaxel (dose 60 mg/m2). The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2. The fraction of unbound paclitaxel in plasma ranged from 7.6 to 12.4% (unbound drug CL 176 l/h/m2). The plasma clearance of CrEL was 0.332 l/h/m2, whereas CrEL levels were undetectable in CSF (below 0.5 μl/ml). Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53%) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84 ± 3.6% (range 81-88%). These findings indicate that there is substantial distribution of paclitaxel to CSF. Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration.

Original languageEnglish (US)
Pages (from-to)365-368
Number of pages4
JournalAnti-Cancer Drugs
Volume14
Issue number5
DOIs
StatePublished - Jun 2003

Fingerprint

Paclitaxel
Cerebrospinal Fluid
Pharmaceutical Preparations
Liquid Chromatography
Half-Life
Dialysis
Coloring Agents
Breast Neoplasms
cremophor EL

Keywords

  • Cerebrospinal fluid
  • Cremophor EL
  • Mass spectrometry
  • Paclitaxel
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Gelderblom, H., Baker, S. D., Zhao, M., Verweij, J., & Sparreboom, A. (2003). Distribution of paclitaxel in plasma and cerebrospinal fluid. Anti-Cancer Drugs, 14(5), 365-368. https://doi.org/10.1097/00001813-200306000-00007

Distribution of paclitaxel in plasma and cerebrospinal fluid. / Gelderblom, Hans; Baker, Sharyn D.; Zhao, Ming; Verweij, Jaap; Sparreboom, Alex.

In: Anti-Cancer Drugs, Vol. 14, No. 5, 06.2003, p. 365-368.

Research output: Contribution to journalArticle

Gelderblom, H, Baker, SD, Zhao, M, Verweij, J & Sparreboom, A 2003, 'Distribution of paclitaxel in plasma and cerebrospinal fluid', Anti-Cancer Drugs, vol. 14, no. 5, pp. 365-368. https://doi.org/10.1097/00001813-200306000-00007
Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Distribution of paclitaxel in plasma and cerebrospinal fluid. Anti-Cancer Drugs. 2003 Jun;14(5):365-368. https://doi.org/10.1097/00001813-200306000-00007
Gelderblom, Hans ; Baker, Sharyn D. ; Zhao, Ming ; Verweij, Jaap ; Sparreboom, Alex. / Distribution of paclitaxel in plasma and cerebrospinal fluid. In: Anti-Cancer Drugs. 2003 ; Vol. 14, No. 5. pp. 365-368.
@article{aae684c4f8684d76ab87cdda5c6a8a16,
title = "Distribution of paclitaxel in plasma and cerebrospinal fluid",
abstract = "Our objective was to assess the distribution of paclitaxel in plasma and cerebrospinal fluid (CSF) in a cancer patient, and evaluate the role of the formulation vehicle Cremophor EL (CrEL) in drug distribution. Analysis of paclitaxel concentrations in CSF was performed using a triple-quadrupole mass spectrometric assay with electrospray ionization. Total and unbound paclitaxel levels in plasma were measured by liquid chromatography and equilibrium dialysis, respectively, and CrEL concentrations were determined by a colorimetric dye-binding microassay. Clinical samples were obtained from a 54-year-old female with breast cancer receiving a weekly regimen of paclitaxel (dose 60 mg/m2). The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2. The fraction of unbound paclitaxel in plasma ranged from 7.6 to 12.4{\%} (unbound drug CL 176 l/h/m2). The plasma clearance of CrEL was 0.332 l/h/m2, whereas CrEL levels were undetectable in CSF (below 0.5 μl/ml). Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53{\%}) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84 ± 3.6{\%} (range 81-88{\%}). These findings indicate that there is substantial distribution of paclitaxel to CSF. Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration.",
keywords = "Cerebrospinal fluid, Cremophor EL, Mass spectrometry, Paclitaxel, Pharmacokinetics",
author = "Hans Gelderblom and Baker, {Sharyn D.} and Ming Zhao and Jaap Verweij and Alex Sparreboom",
year = "2003",
month = "6",
doi = "10.1097/00001813-200306000-00007",
language = "English (US)",
volume = "14",
pages = "365--368",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Distribution of paclitaxel in plasma and cerebrospinal fluid

AU - Gelderblom, Hans

AU - Baker, Sharyn D.

AU - Zhao, Ming

AU - Verweij, Jaap

AU - Sparreboom, Alex

PY - 2003/6

Y1 - 2003/6

N2 - Our objective was to assess the distribution of paclitaxel in plasma and cerebrospinal fluid (CSF) in a cancer patient, and evaluate the role of the formulation vehicle Cremophor EL (CrEL) in drug distribution. Analysis of paclitaxel concentrations in CSF was performed using a triple-quadrupole mass spectrometric assay with electrospray ionization. Total and unbound paclitaxel levels in plasma were measured by liquid chromatography and equilibrium dialysis, respectively, and CrEL concentrations were determined by a colorimetric dye-binding microassay. Clinical samples were obtained from a 54-year-old female with breast cancer receiving a weekly regimen of paclitaxel (dose 60 mg/m2). The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2. The fraction of unbound paclitaxel in plasma ranged from 7.6 to 12.4% (unbound drug CL 176 l/h/m2). The plasma clearance of CrEL was 0.332 l/h/m2, whereas CrEL levels were undetectable in CSF (below 0.5 μl/ml). Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53%) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84 ± 3.6% (range 81-88%). These findings indicate that there is substantial distribution of paclitaxel to CSF. Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration.

AB - Our objective was to assess the distribution of paclitaxel in plasma and cerebrospinal fluid (CSF) in a cancer patient, and evaluate the role of the formulation vehicle Cremophor EL (CrEL) in drug distribution. Analysis of paclitaxel concentrations in CSF was performed using a triple-quadrupole mass spectrometric assay with electrospray ionization. Total and unbound paclitaxel levels in plasma were measured by liquid chromatography and equilibrium dialysis, respectively, and CrEL concentrations were determined by a colorimetric dye-binding microassay. Clinical samples were obtained from a 54-year-old female with breast cancer receiving a weekly regimen of paclitaxel (dose 60 mg/m2). The disposition of total paclitaxel in plasma was characterized by a bi-exponential elimination (terminal half-life 9.17 h) and a total clearance of 19.4 l/h/m2. The fraction of unbound paclitaxel in plasma ranged from 7.6 to 12.4% (unbound drug CL 176 l/h/m2). The plasma clearance of CrEL was 0.332 l/h/m2, whereas CrEL levels were undetectable in CSF (below 0.5 μl/ml). Concentrations of paclitaxel in CSF (range 45.5-162 pg/ml) and unbound CSF:unbound plasma concentration ratios (range 0.093-9.53%) progressively increased up to 24 h, with a mean unbound drug fraction in CSF of 84 ± 3.6% (range 81-88%). These findings indicate that there is substantial distribution of paclitaxel to CSF. Since the fraction of unbound paclitaxel is different between plasma and CSF, measurement of unbound paclitaxel is required to accurately assess the extent of drug penetration.

KW - Cerebrospinal fluid

KW - Cremophor EL

KW - Mass spectrometry

KW - Paclitaxel

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0038178861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038178861&partnerID=8YFLogxK

U2 - 10.1097/00001813-200306000-00007

DO - 10.1097/00001813-200306000-00007

M3 - Article

C2 - 12782943

AN - SCOPUS:0038178861

VL - 14

SP - 365

EP - 368

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -